Hypothesis\n\nAging disrupts the intestinal Wnt morphogen gradient not only by lowering Wnt3 ligand and raising Notum from Paneth cells, but also by depriving the niche of microbiota‑derived short‑chain fatty acids (SCFAs) that normally restrain Notum secretion via GPR43‑mediated signaling. We propose that restoring SCFA production—either through supplementation with SCFA‑producing strains (e.g., Faecalibacterium prausnitzii) or direct acetate/propionate administration—will inhibit Paneth cell Notum expression, thereby allowing Wnt3 to re‑establish a steep crypt‑villus gradient. Concurrently, NAD⁺‑precursor‑driven SIRT1 activation stabilizes β‑catenin, amplifying Wnt transcriptional output and creating a positive feedback loop that further suppresses Notum. This combined metabolic‑microbiome‑Wnt axis resets gradient topology, expands functional crypt number, and rejuvenates ISC regenerative capacity without provoking tumorigenic Wnt hyperactivity because SCFA‑SIRT1 signaling also engages APC‑dependent β‑catenin degradation controls.\n\n### Testable Predictions\n\n1. Spatial rescue – In aged mice, oral gavage with acetate (150 mM) or a defined SCFA‑producing consortium will increase Wnt3 ligand signal at the crypt base and decrease Notum staining, measurable by multiplexed spatial transcriptomics (e.g., 10x Visium) within 7 days.\n2. Functional readout – The same treatment will raise Lgr5⁺ ISC frequency, organoid forming efficiency, and recovery after irradiation injury, comparable to Wnt3a supplementation or Notum inhibition.\n3. Mechanistic dependence – Genetic ablation of Gpr43 in Paneth cells (Vil‑Cre;Gpr43^fl/fl) will block the SCFA‑mediated reduction of Notum and fail to restore ISC function, confirming the receptor’s role.\n4. Synergy with NAD⁺ – Combining acetate with nicotinamide riboside (NR) will produce a greater increase in nuclear β‑catenin and downstream Axin2 expression than either alone, yet will not elevate phospho‑histone H3⁺ proliferative indices beyond youthful levels, indicating a safety window.\n5. Cancer risk – Long‑term (6‑month) treatment will not increase adenoma formation in APC^Min/+ mice; instead, SCFA‑NR will reduce tumor burden relative to Wnt3a monotherapy, reflecting preserved β‑catenin turnover.\n\n### Falsifiability\n\nIf SCFA administration fails to alter Paneth cell Notum or Wnt3 levels, does not improve ISC metrics, or requires Gpr43‑independent pathways, the core premise—that microbiota‑derived SCFAs directly temper Notum to shape the Wnt gradient—is refuted. Likewise, lack of synergistic effect with NAD⁺ precursors would challenge the proposed metabolic‑Wnt feedback.\n\n### Broader Impact\n\nValidating this hypothesis would unite three geroprotective strategies—microbiome modulation, NAD⁺ boosting, and fine‑tuned Wnt signaling—into a mechanistic framework where metabolite‑receptor signaling maintains niche morphogen integrity. It would also guide therapeutic design: precision dosing of SCFAs alongside NAD⁺ precursors could rejuvenate gut stem cells while mitigating oncogenic risk, a balance elusive with blunt Wnt agonists.\n\n---\n\nKey References\n- Wnt decline & Notum rise in aging ISC niche [https://pmc.ncbi.nlm.nih.gov/articles/PMC5987258/]\n- Microbiota transplant reverses ISC aging [https://pmc.ncbi.nlm.nih.gov/articles/PMC9603545/]\n- NAD⁺ precursors rejuvenate gut stem cells [https://www.isscr.org/isscr-news/new-study-shows-gut-microbiota-directly-regulates-intestinal-stem-cell-aging]\n- IFN‑γ and ERK‑MAPK shift in aged niche [https://doi.org/10.1111/acel.12935]\n- Safety of intestinal stem cell protection [https://medicalxpress.com/news/2025-02-safeguarding-intestinal-stem-cells-aging.html]\n- Aging, niche, and colorectal cancer link [https://themarkfoundation.org/portfolio/impact-of-aging-on-the-intestinal-stem-cell-niche-and-colorectal-cancer/]
